Basic Information
SELEGOS TABLET 5 mg
TABLET
Regulatory Information
SIN08681P
April 30, 1996
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XN04BD01
Company Information
Active Ingredients
SELEGILINE HCl
Strength: 5 mg
Detailed Information
Contraindications
**4.3. Contraindications** None.
Indication Information
**4.1. Therapeutic indications** SELEGOS is indicated for the treatment of Parkinson’s disease or symptomatic parkinsonism. SELEGOS may be used alone in early Parkinson’s disease to delay the need for levodopa (with or without decarboxylase inhibitor). SELEGOS may also be used as an adjunct to levodopa (with or without decarboxylase inhibitor).